Urokinase-type plasminogen activator receptor crosslinking in an NK cell line increases integrin surface expression by the MAP kinase/ERK 1/2 signaling pathway

Journal of Cellular Biochemistry

Volumn 89, Issue 2, 2003, Pages 279-288

  Gellert, Ginelle C ^a   Kitson, Richard P ^a   Goldfarb, Ronald H ^a,b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b Sopherion Therapeutics Inc   (United States)

Author keywords

Integrins; MAP kinase; NK cells; Urokinase receptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; GLYCOSYLPHOSPHATIDYLINOSITOL; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; UO 126; UROKINASE RECEPTOR;

ADOPTIVE TRANSFER; ARTICLE; CELL ADHESION; CELL MEMBRANE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE; ENZYME ACTIVATION; FLAVONOIDS; FLOW CYTOMETRY; HUMANS; INTEGRINS; KILLER CELLS, NATURAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, CELL SURFACE;

EID: 0038372578     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10512     Document Type: Article

References (46)

1. Aguirre Ghiso JA, Kovalski K, Ossowski L. 1999. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147:89-104.
2. Al-Atrash G, Kitson RP, Xue Y, Goldfarb RH. 2000. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion. In Vivo 14:565-570.
3. Al-Atrash G, Kitson RP, Xue Y, Mazar AP, Kim MH, Goldfarb RH. 2001. uPA and uPAR contribute to NK cell invasion through the extracellular matrix. Anticancer Res 21:1697-1704.
4. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH. 1991a. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174:479-488.
5. Basse PH, Nannmark U, Johansson BR, Herberman RB, Goldfarb RH. 1991b. Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Natl Cancer Inst 83:944-950.
6. Bianchi E, Ferrero E, Fazioli F, Mangili F, Wang J, Bender JR, Blasi F, Pardi R. 1996. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest 98:1133-1141.
7. Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. 1995. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 181:1381-1390.
8. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. 1994. Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells. J Cell Biol 126:259-270.
9. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP. 1999. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 59:5307-5314.
10. Chapman HA, Wei Y, Simon DI, Waltz DA. 1999. Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 82:291-297.
11. Dumler I, Weis A, Mayboroda OA, Maasch C, Jerke U, Haller H, Gulba DC. 1998. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 273:315-321.
12. Dumler I, Kopmann A, Wagner K, Mayboroda OA, Jerke U, Dietz R, Haller H, Gulba DC. 1999. Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells. J Biol Chem 274:24059-24065.
13. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD. 1990. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111:783-792.
14. Goldfarb RH, Timonen T, Herberman RB. 1984. Production of plasminogen activator by human natural killer cells. Large granular lymphocytes. J Exp Med 159:935-951.
15. Gyetko MR, Todd RF III, Wilkinson CC, Sitrin RG. 1994. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93:1380-1387.
16. Herberman RB, Hiserodt J, Vujanovic N, Balch C, Lotzova E, Bolhusi R, Golub S, Lanier LL, Philips JH, Riccardi C, Ritz J, Santoni A, Schmidt RE, Uchida A. 1987. Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleen. Immunol Today 8:178-181.
17. Jo M, Thomas KS, Somlyo AV, Somlyo AP, Gonias SL. 2002. Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J Biol Chem 277:12479-12485.
18. Konakova M, Hucho F, Schleuning WD. 1998. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem 253:421-429.
19. Koshelnick Y, Ehart M, Hufnagl P, Heinrich PC, Binder BR. 1997. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J Biol Chem 272:28563-28567.
20. Kuppen PJ, van der Eb MM, Jonges LE, Hagenaars M, Hokland ME, Nannmark U, Goldfarb RH, Basse PH, Fleuren GJ, Hoeben RC, van de Velde CJ. 2001. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem Cell Biol 115:67-72.
21. Kusch A, Tkachuk S, Haller H, Dietz R, Gulba DC, Lipp M, Dumler I. 2000. Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. J Biol Chem 275:39466-39473.
22. Li C, Liu JN, Gurewich V. 1995. Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction. J Biol Chem 270:30282-30285.
23. Maenpaa A, Jaaskelainen J, Carpen O, Patarroyo M, Timonen T. 1993. Expression of integrins and other adhesion molecules on NK cells: Impact of IL-2 on short- and long-term cultures. Int J Cancer 53:850-855.
24. Myohanen HT, Stephens RW, Hedman K, Tapiovaara H, Ronne E, Hoyer-Hansen G, Dano K, Vaheri A. 1993. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem 41:1291-1301.
25. Nannmark U, Johansson BR, Bryant JL, Unger ML, Hokland ME, Goldfarb RH, Basse PH. 1995. Microvessel origin and distribution in pulmonary metastases of B16 melanoma: Implication for adoptive immunotherapy. Cancer Res 55:4627-4632.
26. Nguyen DH, Webb DJ, Catling AD, Song Q, Dhakephalkar A, Weber MJ, Ravichandran KS, Gonias SL. 2000. Urokinase-type plasminogen activator stimulates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps - Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem 275:19382-19388.
27. Ossowski L, Aguirre-Ghiso JA. 2000. Urokinase receptor and integrin partnership: Coordination of signaling for cell adhesion, migration, and growth. Curr Opin Cell Biol 12:613-620.
28. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD. 1993. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122:673-684.
29. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. 1996. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15:1572-1582.
30. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492.
31. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897.
32. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676-1680.
33. Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ. 1988. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 48:5007-5010.
34. Simon DI, Wei Y, Zhang L, Rao NK, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman HA. 2000. Identification of a urokinase receptor - integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 275:10228-10234.
35. Sitrin RG, Todd RF III, Albrecht E, Gyetko MR. 1996. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 97:1942-1951.
36. Sitrin RG, Pan PM, Harper HA, Blackwood RA, Todd RF III. 1999. Urokinase receptor (CD87) aggregation triggers phosphoinositide hydrolysis and intracellular calcium mobilization in mononuclear phagocytes. J Immunol 163:6193-6200.
37. Sitrin RG, Pan PM, Harper HA, Todd RF III, Harsh DM, Blackwood RA. 2000. Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils. J Immunol 165:3341-3349.
38. Stahl A, Mueller BM. 1994. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 54:3066-3071.
39. Stahl A, Mueller BM. 1997. Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system. Int J Cancer 71:116-122.
40. Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE. 1998. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 273:18268-18272.
41. van der Pluijm G, Sijmons B, Vloedgraven H, van der Bent C, Drijfhout JW, Verheijen J, Quax P, Karperien M, Papapoulos S, Lowik C. 2001. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 159:971-982.
42. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. 1999. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 144:1285-1294.
43. Xue W, Kindzelskii AL, Todd RF III, Petty HR. 1994. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 152:4630-4640.
44. Xue W, Mizukami I, Todd RF III, Petty HR. 1997. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res 57:1682-1689.
45. Yebra M, Parry GC, Stromblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. 1996. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem 271:29393-29399.
46. Yebra M, Goretzki L, Pfeifer M, Mueller BM. 1999. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 250:231-240.